Navigation Links
InterMune Reports Third Quarter 2010 Financial Results
Date:10/28/2010

uch differences include, but are not limited to, those discussed in detail under the heading "Risk Factors" in InterMune's most recent annual report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 15, 2010 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and the risk that InterMune's revenue will continue to decline as expected; (ii) risks related to significant regulatory, supply and competitive barriers to entry with respect to Actimmune; (iii) risks related to the uncertain, lengthy and expensive clinical development and regulatory process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues; (iv) risks related to achieving positive clinical trial results for the company's product candidates; (v) risks related to timely patient enrollment and retention in clinical trials involving the company's product candidates; (vi) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the FDA or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (vii) the results as reported by Shionogi concerning their Phase 3 trial of pirfenidone for the treatment of IPF may differ from those published or presented in a peer-reviewed forum; and (viii) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue.  The risks and other factors discussed above should be considered only in
'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. InterMune Announces Four Oral Presentations on Pirfenidone and IPF at the Annual Congress of the European Respiratory Society (ERS)
2. InterMune to Release Second Quarter Financial Results on July 27
3. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
4. FDA Advisory Committee Recommends Approval of InterMunes Esbriet(R) (pirfenidone) for Idiopathic Pulmonary Fibrosis
5. InterMune Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Pirfenidone
6. InterMune Reports Fourth Quarter and Full Year 2009 Financial Results and Business Highlights
7. InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
8. InterMune to Present at Deutsche Bank Biotech Confab
9. InterMune Reports Third Quarter 2009 Financial Results and Business Highlights
10. InterMune Announces Submission of NDA for Pirfenidone for the Treatment of Patients with IPF
11. InterMune to Present at JMP Securities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014  Actavis plc (NYSE: ... received a complete response letter from the U.S. ... Drug Application (NDA) for the fixed-dose combination (FDC) ... hypertension.   Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... the receipt of a complete response letter, Actavis ...
(Date:12/24/2014)... 2014 Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... that on December 24, 2014 it closed its ... Company raised approximately $2.3 million in gross proceeds ... net proceeds from the offering to fund its ...
(Date:12/24/2014)... CRANBURY, N.J. and FARMINGTON, ... Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical ... treatment of diseases with significant unmet medical need ... closed on a private placement of 2,050,000 shares ... to purchase 24,949,325 shares of its common stock.  ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... the popularity of,fillers becoming mainstream, it,s no surprise ... facial wrinkles. Dr. Arnold Klein, world,renowned cosmetic dermatologist ... such as Artefill, Radiesse and Sculptra contain injectable,plexiglass, ... all of,these products can cause foreign body reactions," ...
... in the Annals,of Emergency Medicine ("Increasing Rates of Emergency ... to 2003") finds the rate of,elderly Americans seeking emergency ... Kenneth L. Noller, MD, President of the American College ... on behalf of the Alliance of Specialty Medicine., ...
... warn of surge in cardiovascular troubles by 2035 , , ... adolescents are more likely to be overweight or obese ... and death, two new studies conclude. , The first, ... are at an increased risk of coronary heart disease ...
... LANCASTER, Pa., Dec. 5 Eastern Insurance,Holdings, Inc. (Nasdaq: ... board of directors has authorized a $0.05 per share ... common stock, payable,December 28, 2007 to shareholders of record ... EIHI is the parent company of Eastern Life and ...
... Pharmaceuticals, Inc.,(Nasdaq: IDEV ) today announced the Company ... Thursday, December 13, 2007 at 12:30 PM,Eastern Time. The ... will be web cast live and may be accessed ... http://www.indevus.com ., About Indevus, Indevus Pharmaceuticals, ...
... (SACRAMENTO, Calif.) -- Apart from a more complicated ... amounts of time with their patients" Researchers at ... practice-specific characteristics that affect the length of a ... satisfaction with the doctors visit. , In ...
Cached Medicine News:Health News:Facial Deformity Danger? 2Health News:Dramatic Growth Projected in Visits by Elderly Patients to Emergency Departments Underscores Urgency of Medicare Physician Payment Fix 2Health News:Overweight Kids Often Become Obese, Unhealthy Adults 2Health News:Overweight Kids Often Become Obese, Unhealthy Adults 3Health News:Eastern Insurance Holdings, Inc. Announces Quarterly Dividend 2Health News:Eastern Insurance Holdings, Inc. Announces Quarterly Dividend 3Health News:Indevus Pharmaceuticals To Present at RBC Capital Markets Conference 2Health News:Indevus Pharmaceuticals To Present at RBC Capital Markets Conference 3Health News:New UC Davis study finds physician style and HMO affiliation impact lengths of patient visit 2
... This BioSafe room is configured specifically ... and chemical analysis. Panels are precision-joined ... easy to wipe down and disinfect. ... double-wall panel design creates strong, rigid ...
... Features hardwall acrylic panels ... frame to form a free-standing ... to Class 10/ISO 3. Optional ... and ionizers are configured to ...
... curtains or parting strip shields ... frame to form a free-standing, ... cleanliness to Class 10/ISO 3. ... lights, and ionizers are configured ...
... cleanroom for biological safety labs (BSL) ... (to Class 10/ISO 3) and easy ... ultra-smooth surfaces that are easy to ... corners simplify cleaning. Unique double-wall panel ...
Medicine Products: